[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-343496-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-343496-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","gb18-06-a-nanobody-targeting-gdf15-effectively-alleviates-weight-loss-and-restores-physical-function-in-cachexia-models","GB18-06, a nanobody targeting GDF15, effectively alleviates weight loss and restores physical function in cachexia models","","Cachexia is a complex metabolic syndrome commonly linked to cancers, marked by severe weight loss and muscle wasting that worsen prognosis and survival. No pharmacological treatment currently reverses weight loss or improves physical performance in cachexia patients. Growth differentiation factor 15 (GDF15) suppresses appetite and helps regulate energy balance via GFRAL. To create a targeted therapy, researchers generated a GDF15-targeting VHH nanobody, GB18–06, with high affinity, which blocks GDF15–GFRAL signaling, reduces ERK and AKT phosphorylation, and alleviates weight loss in mouse cachexia models, while improving ambulatory activity and showing favorable pharmacokinetics and developability.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/gb18-06-a-nanobody-targeting-gdf15-effectively-alleviates-weight-loss-and-restores-physical-function-in-cachexia-models/343496/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/gb18-06-a-nanobody-targeting-gdf15-effectively-alleviates-weight-loss-and-restores-physical-function-in-cachexia-models/343496.png","ImageObject",300,407,{"name":42,"@type":43},"River Wang","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-12","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the study address?","Question",{"text":63,"@type":64},"The study addresses cancer cachexia, a debilitating metabolic syndrome involving extreme weight loss and muscle wasting with no effective pharmacological treatment to reverse it or improve physical performance.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does GB18–06 work at the molecular level?",{"text":68,"@type":64},"GB18–06 is a GDF15-targeting VHH nanobody that binds GDF15 with high affinity and inhibits the GDF15–GFRAL signaling pathway, leading to reduced downstream ERK and AKT phosphorylation.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key in vivo outcomes in cachexia models?",{"text":72,"@type":64},"In mouse models of cancer and chemotherapy-induced cachexia, GB18–06 alleviated weight loss by more than 20% and increased ambulatory activity by 77% compared with the control group.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},343496,1790597003,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","REPORT  \nGB18-06, a nanobody targeting GDF15, effectively alleviates weight loss and restores physical function in cachexia models  \nYu Huang, Jinyong Wang, Xiling Wei, Hui Zhang, Wei Shang, Xiangling Zhang, Lanjiao Zhai, Xi Chen, Huiming Li, and Suofu Qin  \nDrug Discovery, Center for Research and Development, Kexing Biopharm Co. Ltd, Shenzhen, China  \nABSTRACT  \nCachexia is a complicated metabolic syndrome mainly associated with cancers, characterized by extreme weight loss and muscle wasting. It is a debilitating condition that negatively affects prognosis and survival. However, there is currently no effective pharmacological intervention that can reverse body weight loss and improve physical performance in patients with cachexia. Growth differentiation factor 15 (GDF15) can suppress appetite and regulate energy balance through binding to glial cell-derived neurotrophic factor receptor alpha-like (GFRAL) . In order to develop a novel, effective treatment for cachexia, we generated a GDF15-targeting VHH nanobody, GB18–06, that was able to bind GDF15 with high affinity. In vitro, GB18–06 potently inhibited the GDF15-GFRAL signaling pathway, leading toa reduction of downstream ERK and AKT phosphorylation levels; in vivo, GB18–06 alleviated weight loss (>20%) in cancer and chemotherapy-induced cachexia models in mice. Compared with the control (phosphate-buffered saline) group, the ambulatory activity of mice in the GB18–06-treated group also increased 77% . Furthermore, GB18–06 exhibited desirable pharmacokinetic properties and an excellent developability profile. Our study has demonstrated a means of developing targeted treatment for cachexia with high efficacy, potentially leading to improved clinical outcomes and quality of life for patients with cachexia.  \nARTICLE HISTORY  \nReceived 17 August 2024 Revised 7 October 2024 Accepted 9 October 2024  \nKEYWORDS  \nCachexia; Cancer;  \nChemotherapy; GDF15; Nanobody  \nIntroduction  \nCachexia is a metabolic syndrome characterized by unintended weight loss, muscle wasting, and decreased physical performance, which often does not completely resolve with conventional nutritional support 1. Cachexia is a serious complication caused by metabolic disorders, systemic inflammation and other pathophysiological factors frequently associated with chronic diseases, including advanced malignant cancers.2,3 Manifested clinically by anorexia, skeletal muscle atrophy and multiple organs dysfunction, cancer cachexia (CC) negatively impacts prognosis and survival and accounts for 20−30% of all deaths related to cancer.4 Currently, there is no effective treatment for CC.5 As reported in clinical trials in patients with non-small cell lung cancer (NSCLC),6,7 anamorelin, a small molecule agonist of ghrelin receptor yielded significant increase in total body weight and lean body mass, but no improvement in physical function, represented by handgrip strength, was reported. The marginal effects associated with this medication have apparently made approval challenging, as it is currently marketed in only one country (Japan) . Therefore, CC remains a major unmet medical need to be addressed through more effective pharmacological intervention.  \nGrowth differentiation factor 15 (GDF15), a distant member of the transformed growth factor-beta (TGF-β) superfamily, is a stress-responsive cytokine. GDF15 plays a major role in appetite  \ncontrol and is considered a master metabolic regulator; however, in chronic disease states, it is directly involved in the pathogenesis of CC.8 GDF15 regulates energy balance and suppresses appetite by activating GFRAL, which is selectively expressed in the area postrema and nucleus of the solitary tract of the hindbrain.9 Elevated serum GDF15 level is a predictive indicator of poor prognosis in many types of cancer and is associated with weight loss in patients with CC.10 Preclinical studies in mouse models and non-human primates have shown that the production of GDF15 promotes the ","cbCait1jKKN9oXew","https://ap.wps.com/l/cbCait1jKKN9oXew","pdf",2207290,13,"English","# Abstract\n# Introduction\n## Cachexia and unmet medical need\n## Role of GDF15 and GFRAL in cachexia\n## Nanobodies as therapeutics\n## Study overview and GB18–06 rationale","[{\"question\":\"What problem does the study address?\",\"answer\":\"The study addresses cancer cachexia, a debilitating metabolic syndrome involving extreme weight loss and muscle wasting with no effective pharmacological treatment to reverse it or improve physical performance.\"},{\"question\":\"How does GB18–06 work at the molecular level?\",\"answer\":\"GB18–06 is a GDF15-targeting VHH nanobody that binds GDF15 with high affinity and inhibits the GDF15–GFRAL signaling pathway, leading to reduced downstream ERK and AKT phosphorylation.\"},{\"question\":\"What were the key in vivo outcomes in cachexia models?\",\"answer\":\"In mouse models of cancer and chemotherapy-induced cachexia, GB18–06 alleviated weight loss by more than 20% and increased ambulatory activity by 77% compared with the control group.\"}]","GB18-06, a nanobody targeting GDF15, effectively alleviates weight loss and restores physical function in cachexia models | PDF",1790051315,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5a649c73c1a72e0d9a3462576a6281eb.webp",983,1280,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1e02b7d39a067b91bb658aac3b100324.webp",982,1278,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e490bae24865ad7f197c2a34e0661964.webp",981,1277,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cdcf764b2552312901edf0c8a5be9450.webp",980,1276]